| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.43 | 4e-13 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.42 | 3e-12 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.29 | 2e-10 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.45 | 2e-09 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.42 | 6e-09 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.26 | 1e-08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.26 | 3e-08 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 6e-08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-07 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.22 | 5e-07 |